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Subsequent pregnancies (SSPs) in patients with peripartum cardiomyopathy (PPCM) have a 
high risk of heart failure relapse. We report on outcome of SSPs in PPCM patients in South 
Africa. 
 
METHODS AND RESULTS 
Of the 18 PPCM patients with a SSP, 3 patients died within 6-months follow-up. Overall 
relapse rate, left ventricular ejection fraction (LVEF) <50% or death after at least 6 months 
follow-up, was 30%, with 16% (3/18) mortality. Persistently reduced LVEF (<50%) before 
entering SSP was present in 44% of patients, while full recovery (LVEF≥ 50%) was present in 
85%. Persistently reduced LVEF before SSP was associated with a higher mortality (27% vs 0%) 
and a lower rate of full recovery at follow-up. Patients obtaining standard therapy for heart 
failure and bromocriptine immediately after delivery displayed significantly better LVEF at 
follow-up and a higher rate of full recovery, with no patient dying, compared with patients 
obtaining standard therapy for heart failure alone. 
 
CONCLUSION 
Full recovery of LVEF before SSP was associated with lower mortality and better cardiac 
function at follow-up. Addition of bromocriptine to standard therapy for heart failure 
immediately after delivery was safe and appeared to be associated with better outcome of 










Peripartum cardiomyopathy (PPCM) is a disorder of unknown origin in which symptoms of 
heart failure occur between the last month of pregnancy and 5 months postpartum. By 
definition, PPCM occurs in the absence of an identifiable cause of heart failure, and in the 
absence of recognisable heart disease, prior to the last month of pregnancy. Some authors go 
beyond this defined time frame to include patients diagnosed with heart failure as early as 3 
months pregnancy {Elkayam, 2005 #30}.  
 
Diagnosis requires echocardiographic evidence of left ventricular systolic dysfunctional 
(ejection fraction (EF) <45%) {Chapa, 2005 #111}. Heart failure that occurs in earlier pregnancy 
may be caused by previously unsuspected familial or other forms of cardiomyopathy that 
(unmarked by the hemodynamic and hormonal stress of pregnancy) forms a different entity. 
Diagnosis of PPCM should be established by ruling out other causes of perinatal heart failure, 
such as infectious diseases, metabolic disorders and ischaemic or vulvar heart disease. 
Complications of late pregnancy that may have similar symptoms and signs of PPCM include 
pre-eclampsia, amniotic or pulmonary embolism, haemolysis, elated liver enzymes and low 
platelets {Kist, 2008 #25}.  
 
The American College of Cardiology (ACC) guidelines classify PPCM as an entity on its own 
{Maron, 2006 #26}. However, in the recently published European Society of Cardiology 
classification, PPCM is not listed as a specific disease and is placed under the category of 
“unclassified cardiomyopathies”. Although approximately 20% of women with the disorder 
either die or survive only because they receive cardiac transplants, the majority recover 
partially or completely. Although the women who recover may desire to become pregnant 
again, there is a concern that these SSPs may be associated with an increased risk of 
recurrence of cardiomyopathy.  
 
PPCM is most common in women of African descent, but it has been reported in all major 
ethnic populations. The incidence varies from 1:100 to 1:1000 between geographic regions 
due to diagnostic limitations, including limited access to echocardiography and the incidence 
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may, in some areas, be over-estimated. There is considerable controversy regarding the 
aetiology of human PPCM, but a number of recent publications have contributed to a better 
understanding of its pathogenesis. A number of mechanisms have been proposed in the 
development of PPCM, including nutrition deficiencies, genetic disorders, viral or 
autoimmune aetiologies, hormonal imbalances, volume overload, alcohol, physiologic stress 
of pregnancy and unmasking of latent idiopathic dilated cardiomyopathy (DCMO){Sliwa, 2006 
#27}. However, none of these mechanisms have been confirmed in detailed investigations or 
prospective studies {Fett, 2002 #128}. The rare incidence of PPCM and the paucity of relevant 
animal models have limited guided research and the understanding of pathogenic 
mechanisms involved. Some authors have suggested that multiparty may be a risk factor for 
PPCM. However, a study by Elkayam et al 2005 does not support this theory within a cohort 
in the United States as almost 40% of the cases occurred in association with a first pregnancy, 
and more than 50% within the first two pregnancies. Features of a normal pregnancy include 
expansion of blood volume, an increase in metabolic demands, relative anaemia and changes 
in vascular resistance that are associated with mild ventricular dilatation and an in increase 
in cardiac output. These physiologic changes are due to an increase in preload and heart rate, 
accompanied by a decrease in afterload. Decompensation of patients with subclinical vulvular 
ischaemic or myophathic heart disease usually occur during the second or third trimester of 
pregnancy {Elkayam, 2005 #30}.  
The onset of PPCM can be easily missed because many symptoms and signs of pregnancy and 
post pregnancy stages are similar to those of early congestive heart failure (CHF), e.g. 
dyspnoea, abdominal discomfort and fatigue {MB., 1995 #168}.  In a study by Elkayam et 
al(2005) reported that 7% of their patients in the United States were diagnosed within 1 
month before delivery, whereas 75% were diagnosed during the first month postpartum, the 
remainder having fulfilled criteria for PPCM before the last 1 month of pregnancy{Elkayam, 
2005 #30}. In contrast, a study by Sliwa K et al (2000) patients in South Africa and Haiti 
developed symptoms almost exclusively within the postpartum period. The symptoms and 
signs are similar to those in patients with idiopathic DCMO.  
 
PPCM often presents with acute onset of heart failure (AHF). The presentation, with reduced 
cardiac output, tissue perfusion, increase in the pulmonary capillary wedge pressure and 
tissue congestion, is often life-threatening and requires urgent treatment. Chest radiography 
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and other imaging modalities should be conducted early for all patients with AHF to evaluate 
pre-existing chest or cardiac conditions and to assess pulmonary congestion {Sliwa, 2000 #56}.  
 
A number of laboratory tests should be used in all patients with PPCM presenting with AHF - 
full blood count, urea and electrolytes, C-reactive protein (CRP) blood glucose, D-dimer, 
creatine Kinase-MB (CK-MB) and cardiac troponin–T (cTnT). In severe heart failure, 
international normalised ratio and arterial blood gas should be performed. Transaminases, 
urinalysis, plasma B–type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic 
peptide (NT proBNP) can be considered). 
 
Over the past decade, accumulating evidence has suggested distinct pathogenetic 
mechanisms for PPCM, which may differ from those of other forms of dilated cardiomyopathy 
(DCMO). Apoptotic events, systematically and in the myocardium, appear to causally 
associate with PPCM. The apoptotic signalling surface receptor Fas/Apo1 is known to trigger 
cell death in a variety of cell types. Patients with PPCM had significantly higher plasma levels 
of Fas/Apo1, compared with healthy volunteers {Sliwa, 2000 #91}. 
 In a study by Forster et al (2008) the serum markers related to cardiac function, apoptosis, 
oxidative stress, remodelling, inflammation and the nursing hormone prolactin were analysed 
in PPCM patients and healthy controls. The kinetics of these biomarkers were compared 
between patients with Improved cardiac function(IMP) and those patients who did not 
improve(NIMP), over 6 months follow up. After 6 months, NT- proBNP, oxLDL, Interferon 
gamma were significantly lower in IMP group and the decrease in oxLDL, interferon gamma 
and prolactin was significant in IMP group but not in NIMP. Significant correlations were 
observed between the kinetics of NT-proBNP, oxLDL,, prolactin and interferon gamma in 
PPCM patients{Forster, 2008 #169}. One of the most common issues for women surviving an 
episode of PPCM is whether it is safe to become pregnant again. If a subsequent pregnancy 
occurs, it should be managed in close collaboration between the obstetrician and the 
attending physician or a cardiologist. Most authors agree that PPCM patients with persistent 
left ventricular dilatation and dysfunction are at high risk for complications and death should 
they become pregnant again {Sliwa, 2006 #27}. In contrast, the issue of whether patients with 
PPCM and recovered left ventricular function can safely undergo a SSP remains controversial.  
A review study conducted by Elkayam et al (2001) among members of the American College 
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of Cardiology (ACC) in the United States and one hospital in South Africa and described the 
outcome of 60 SSPs in 44 women with a history of PPCM. Among the first SSPs in the 44 
women, 28 occurred among women in whom left ventricular function had returned to normal 
(group 1) and 16 occurred in women with persistent left ventricular dysfunction (group2). 
These pregnancies were associated with a reduction in mean LVEF in each group. 19% of 
PPCM patients with a sustained impaired systolic function, who then conceived their first SSP 
eventually died {Elkayam, 2001 #164}.  Although the likelihood of maternal death seems to 
be very low in women who recorded their left ventricular function before a SSP, a reduction 
in LVEF and symptomatic heart failure will occur in the majority of PPCM patients in SSPs. 
 
 Echocardiography is an essential tool for evaluating the functional and structural changes 
underlying or associated with acute heart failure. The most important measurement of 
ventricular function is LVEF for distinguishing patients with cardiac systolic dysfunction from 
those with preserved systolic function. Echocardiography with Doppler imaging should be 
used to evaluate and monitor regional and global left and right ventricular function, vulvular 
structure and function, possible pericardial pathology and mechanical complications.. 
 
Information about the outcome of additional pregnancies is, however, limited. There is 
therefore no consensus regarding recommendations for future pregnancies in women who 
have had PPCM. 
 
HYPOTHESIS 
Patients with PPCM are at increased risk of recurrence of cardiomyopathy with SSPs.  
 
AIMS 
To investigate both foetal and maternal outcome (clinically and radiologically) of subsequent 
pregnancy in patient with Peripartum Cardiomyopathy. 
OBJECTIVES  
Maternal Outcome 
 To determine the survival of mothers with peripartum cardiomyopathy with a SSP in 
terms of LV systolic function using transthoracic echocardiogram e.g. ejection fractions 
(maternal outcome).  
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 Cytokine measurement especially TNF & at 6 months and 12 months post-partum.  
 
Foetal Outcome 
 To assess the outcome of pregnancies (foetal) of mothers with PPCM that were not 
terminated. The viability of the product of pregnancy using the birth weight and general 
health of the baby (foetal outcome).  
 Mode of delivery e.g. vaginal or Caesarean section 
 Premature delivery – defined as delivery at less than 37 weeks gestation 
 Abortions – whether therapeutic or spontaneous.  
 
What the study hopes to add to the current knowledge 
To determine the impact of PPCM in SSPs, with the aim of improving awareness and 
management of per partum cardiomyopathy patients by health care professionals. Following 
this, proactive strategies can be developed to help patients manage family planning and other 
risk factors associated with PPCM. 
 
METHODS 
This is a retrospective, longitudinal follow-up cohort sub-study of 20 South African patients 
with PPCM who attended Chris Hani Hospital and Groote Schuur Hospital. Twenty patients 
subsequently fell pregnant despite being advised not to fall pregnant.  
 
STUDY DESIGN AND PATIENT RECRUITMENT  
The study was conducted at Chris Hani Baragwanath Hospital (CHB), Soweto and Groote 
Schuur Hospital (GSH), South Africa. Patients were referred from local clinics, secondary 
hospitals and the Department of Obstetrics at Chris Hani Baragwanath and Groote Schuur 
Hospital. 
History of pre-existing cardiac signs or symptoms, pre-eclampsia or eclampsia and mode of 
delivery were obtained from the patient and confirmed by examining the obstetric card 
carried by each patient. Signs and symptoms (baseline) were recorded during first 
presentation at the cardiac unit at Chris Hani Baragwaneth and Groote Schuur Hospital and 





1. Age ≥16 - ≤40. 
2. New York Heart Association classification (NYHA) stage 1 to 4. 
3. Symptoms of heart failure in the last month of pregnancy or postpartum (5 months).  
4. LVEF < 45% echocardiography 
5. Sinus rhythm. 
 
Exclusion Criteria 
1. Organic valvular disease. 
2. Systolic blood pressure ≥170 and blood pressure >05 mmHg 
3. Clinical conditions other than PPCM that would increase cytokines level (HIV, 
Rheumatic Arthritis). 
 
Clinical assessment, echocardiography and cytokine measurements (namely BNP etc.) were 
performed at baseline and after 6 months and 12 months of therapy. Among the 176 patients 
included in the study, 164 (93%) received treatment with furosemide and 141 (80%) were 
treated with an ACE inhibitor. Digoxin was being taken by 113 (64%) of the 176 patients. 
Patients with LVEF <25% or LV thrombus were treated with warfarin. Carvedilol was initiated 
in 100 (57%) of the 176 patients after resolution of overt heart failure. ACE inhibitor and 
carvedilol doses were titrated upward as tolerated throughout the 6 months study period. 
Patients attended the cardiac clinic monthly. These patients were strongly advised to avoid 
new pregnancies and also advised on different modes of contraception and were followed up 
prospectively.  
 
In the group of patients with SSPs, echocardiogram was performed at 6 months of pregnancy 
and 6 and 12 months postpartum. At the same time intervals blood was taken for cytokine 
measurements.  
 
Echocardiography, assessment of New York Heart Association (NYHA) functional class and 




Two-dimensional and targeted M-mode echocardiography with Doppler colour flow mapping 
were performed using a Hewllett Packard Sonos 5500 echocardiograph (Philips, Bothell, 
Washington) attached to a 2,5 or 3,5 – MHZ transducer.  
 
Systolic and LV dimensions were measured according to American Society of 
Echocardiography (ASE) guidelines. LV dimensions and functions were determined using the 
mean of three or more cycles. Echocardiography was taped on video or CD and stored within 
the Soweto cardiovascular research unit division for further reference and audit purposes.  
 
The NYHA functional class of each patient at baseline and follow-up visits was evaluated by a 
physician, who was provided with the clinical information but blinded to the protocol and 
unaware of the results of the laboratory tests.  
 
Blood pressure and heart rate were measured non-invasively with a Critilcon Dinamap vital 
signs monitor 1846 and calculated as mean values from five readings. Measurements were 
made after a 30-minute resting period in the sitting position, with 2 minute intervals between 
successive measurements.  
 
Research Specific blood tests 
Fifteen millilitres of blood was drawn from an antecubital vein and collected in pre-chilled 
evacuated tubes containing ethylenediaminetetra acetic acid or clot activator and mixed 
rapidly. Plasma or serum was separated by centrifugation at 2,500 rpm for 12 minutes within 
15 minutes of collection; the aliquots were frozen at -70⁰C. TNF-α measurements were 
performed using a commercially available enzyme – linked immunoassay (Amersham, 






Database management and statistical analysis will be performed with advice of a 
biostatistician and using an appropriate statistical software. 
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Continuous data will be expressed as mean ± SD or median (range). Comparison of means and 
proportions between groups at baseline will be performed by using independent t–tests (for 
continuous data) and X Statistics or Fisher exact test for categorical data, respectively. 
Wilcoxon rank sums test will be used for comparison of non-parametric baseline data and the 
results at 6 months and 12 months after SSP. Significance will be assumed at a two sided p-
value of <0, 05. Regression analysis will be used to show association of outcome variables for 
survival (Echo values) with predictors (cytokine levels, blood pressure). The sample size is 
based on the available data for 176 patients 
 
Storage of data and information 
All physical data collected during the study will be kept confidentially in a locked area and will 
only be available to authorized staff. Electronic data will also be stored in password–restricted 
computers only accessible to authorized staff.  
 
Publication of Data 
There are no restrictions on the publication of the outcomes of the study. 
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The concept of heart muscle disease has a notable and evolving history. In the mid-1850s, 
chronic myocarditis was the only recognised cause of heart muscle disease. In 1900, the 
designation of primary myocardial disease was introduced, and it was not until 1957 that the 
term "cardiomyopathy " was used for the first time by Maron, Towbin (1).  
 
In 1968, the WHO defined cardiomyopathies as "disease of different and often unknown 
aetiology in which the dominant feature is cardiomegaly and heart failure (2, 3). 
 
In the original 1980 WHO classification, cardiomyopathies were defined only as a "heart 
muscle disease of unknown cause" reflecting a general lack of information available about 
causation and basic disease mechanisms. 
 
In 2006, the American Heart Association (AHA) proposed the following definition: 
"Cardiomyopathies are heterogeneous a group of diseases of the myocardium associated 
with mechanical and/or electrical dysfunction that usually (but not invariably) exhibit 
inappropriate ventricular hypertrophy or dilatation and are due to variety of causes that are 
frequently genetic. Cardiomyopathies are either confined to the heart, or are part of 
generalised systemic disorders, often leading to cardiovascular death or progressive heart 
failure- related disability".  
 
Within this broad definition, cardiomyopathies are usually associated with failure of 
myocardial performance, which may be mechanical (e.g. diastolic or systolic dysfunction) or 
a primary electrical disease prone to life-threatening arrhythmias. 
 
The AHA divides cardiomyopathies into two major groups based on predominant organ 
involvement. Primary cardiomyopathies (genetic, mixed/non-genetic and acquired) are solely 
or predominantly confined to heart muscle and are relatively less common. Secondary 
cardiomyopathies show pathological myocardial involvement as part of a several number of 
systemic pathologies (4).  
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PPCM has been recognised as a serious complication of pregnancy since the 18th century. In 
2000 Pearson et al. defined PPCM as a cardiomyopathy of unknown cause that is 
characterised by symptoms and signs of heart failure associated with decreased left 
ventricular systolic function, occurring between the commencement of the last of pregnancy 
and the end of the fifth month, or in the postpartum period, in women without pre-existing 
symptoms, signs or history of heart disease (5). The disease is associated with a high morbidity 
and mortality, but its aetiology remains unknown. 
 
In 2010, the Working group on PPCM from the Heart Failure Association of the European 
Society of Cardiology (ESC) proposed the following definition of PPCM: "Peripartum 
Cardiomyopathy is an idiopathic cardiomyopathy presenting with heart failure secondary to 
left ventricular systolic dysfunction towards the end of pregnancy, or in the five months 
following delivery, where no other cause of heart failure is found"(6). It is a diagnosis of 
exclusion. The left ventricle may not be dilated but the EF is nearly always below 45%. No 
additional specific criteria have been identified to allow distinction between a peripartum 
patient with new onset heart failure and the left ventricular systolic dysfunction as PPCM and 
another form of dilated cardiomyopathy. This was based on the fact that about 10% of cases 
present with symptoms or are diagnosed 6 months postpartum or even later.  Therefore, all 
other causes of dilated cardiomyopathy with heart failure must be systematically excluded 
before accepting the designation of PPCM (7).   
 
EPIDEMIOLOGY AND PATHOPHYSIOLOGY 
 
The current epidemiological profile of PPCM is largely unknown, with most available data 
coming from Africa, Haiti, and the USA. 
 
Epidemiological studies are complicated by the potential difficulty in initially distinguishing 
PPCM from other forms of cardiomyopathy, such as familial or pre-existing idiopathic dilated 
cardiomyopathy (DCM). Data suggest a wide variation in the estimated incidence of PPCM 
according to geographical region. 
In South Africa, a King Edward VIII hospital study in Durban by Desai, Moodley et al showed a 
high incidence of PPCM in the local population (1:1000) and high complication rate (35%)(8). 
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A Haitian study in 2005 demonstrated an incidence of 1 per 299 live births (9). In USA a study 
by Brar, Khan et al (2007)  showed an overall incidence of PPCM 1 per 4025 live births, with 
African-Americans having the greatest incidence - 7-fold that of Hispanics and 2.9 fold higher 
compared with Whites (10). The incidence of PPCM in Australia, Europe and Asia is uncertain 
and requires more epidemiological studies. The real reason for this geographical variation in 
the incidence of PPCM is unknown, but it may be linked to genetic predisposition and ethnic 
factors (10). 
 
Disease presentation in different ethnic groups might influence left ventricular recovery and 
survival. Outcomes in African-American patients diagnosed with PPCM were similar to those 
in Haiti and South Africa, but lower than those in white US women. Socioeconomic factors 
could limit access to timely and advanced medical care (11). Interestingly, an increase in the 
incidence of PPCM has been reported in the USA, from 1 per 4350 live births in 1990 - 1993, 
to 1 per 2289 live births in 2000 - 2002. The actual increase may be related to the increasing 
maternal age and the rates of multiple births (12). However, it most likely due to increased 
awareness. Enhanced awareness has been promoted by the ESC, the activities of a specialised 
Working Group on PPCM and an international registry of patients with PPCM, as well as the 
international registry of patients with PPCM which is part of the EURObservational Research 
Programme (www.esc.org) 
 
A study by Ntusi, N; Mayosi, B (2009) proposed various mechanisms for aetiology and risk 
factors of PPCM (Fig 1). They conclude that there is conflicting evidence on the pathogenetic 
role of viral myocarditis, abnormal immune response to pregnancy, abnormal response to the 
haemodynamic stress of pregnancy, accelerated myocyte apoptosis, cytokine-induced 
inflammation, malnutrition, genetic factors, excessive prolactin production, abnormal 
hormonal function, increased adrenergic tone, and myocardial ischaemia. The authors 
postulate a number of factors which increase the development of PPCM. These include non-
Caucasian ethnicity, advanced maternal age, multiparty, poor socioeconomic status, multiple 






FAMILIAL AND GENETIC PREDISPOSITION 
 
Pregnancy places physiological stress on the human heart and, unsurprisingly, can unmask 
genetic forms of cardiomyopathy. The increased incidence in particular geographic regions 
suggests that genetic predisposition might have an important role (7).  Morales, Painter et al 
(2010), were able to identify a subset of PPCM patients from their DCM database, designed 
for family-based genetic studies, to be carriers of mutations associated with familial forms of 
DCM involving mutations in PC3, MYH6, MYH7, PSEN2, SCN5A, TNNC1 and TNNT2. Therefore, 
a subset of patients with PPCM may, in fact, be presenting with an initial manifestation of 
familial DCM (14). However, additional genetic factors, independent of the known 
cardiomyopathy, inducing mutations, could potentially also contribute to susceptibility to 
peripartum heart failure (15). 
 
OXIDATIVE STRESS AND ANGIOGENIC IMBALANCE 
 
Oxidative stress is caused by an imbalance between the production of reactive oxygen species 
(ROS: reactive molecule that contain oxygen ions and peroxides are highly reactive owing to 
the presence of unpaired valance- shell electrons) and a biological systems' capacity to 
detoxify ROS or repair the resulting damage. A study by Toescu, Nuttall et al (2002) 
demonstrated that the level of oxidative stress rises during pregnancy and that late pregnancy 
is associated with the formation of particles that are susceptible to oxidation (high LDL 
cholesterol levels) and an increase in oxidative damage. An efficient antioxidant defence may 
even be relevant to the long-term cardiovascular health of women, particularly those of high 
parity or those at high risk of cardiovascular disease (women with diabetes or hypertension) 
(16). 
 
PROLACTIN AND ITS CLEAVED PRODUCTS 
 
The role of prolactin in the pathogenesis of PPCM has been raised in the past. Prolactin is 
associated with an increase in blood volume, decreased blood pressure, decreased 
angiotensin responsiveness, reduced renal excretion of water, sodium and potassium. 
Prolactin also increases the levels of circulating erythropoietin, and, hence, the haematocrit 
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(17). An important advance in this field has been the intriguing discovery of the possible role 
of the production of a 16kDa versus the 23 kDa prolactin in the pathogenesis of PPCM in mice 
and women (18, 19).  Prolactin can exert opposing effects on angiogenesis depending on 
proteolytic processing of the potentially proangiogenic, full-length, 23kDa derivative (20). The 
16kDa N terminal fragment  of prolactin is generated from full- length prolactin by cathepsin 
D, or other proteolytic enzymes such as matrix metalloproteinase’s (MMP): MMP-1, MMP-2, 
MMP-3, MM-8, MMP-9, and MMP-13 produced and secreted by chondrocytes generate 
biologically functional 16kDa prolactin. This 16kDa prolactin is a potent antiangiogenic factor 
(21). A high incidence of PPCM has been discovered in mice with a knockout of the cardiac 
tissue specific signal transduction and activator of transcription-3 (STAT-3), a DNA binding 
protein that is activated by interleukin-6. STAT-3, in addition to mediating cardiomyocyte 
hypertrophy and myocardial angiogenesis also protects the heart from oxidative stress by up-
regulating antioxidative enzymes such as superoxide dismutase. A reduction in STAT-3 leads 
to increased oxidative stress, activation of cathepsin D which leads to the cleavage of prolactin 
into an antiangiogenic and proapoptic 16kDa isoform. The treatment of STAT-3 deficient mice 
with the inhibitor of prolactin secretion, bromocriptine, prevents the development of PPCM 
in these knockout mice (18). Evidence suggests that the angiostatic and proapoptic 16kDa 
prolactin might have a causal role in the initiation and progression of PPCM. Suppression of 
the prolactin release using the D2 dopamine receptor agonist, bromocriptine, prevented the 
onset of disease in several animal models of PPCM (22). This notion is supported by initial 
clinical data from case reports and proof-of-concept pilot studies, which show that the 
addition of bromocriptine to standard therapy for heart failure is associated with 
improvement in both left ventricular function and a composite clinical outcome (remaining in 
NYHA functional class III- IV, failure to improve EF by >10 absolute units, and death) in women 
with acute severe PPCM (23, 24). A few case reports linked the use of bromocriptine, used to 
suppress lactation, with increased incidence of maternal hypertension, strokes, seizures, 
myocardial infarction, an increased pro- coagulant profile, resulting in both arterial 
thrombosis, including intracardiac thrombus formation (25). 
 
In a study by Sliwa, Blauwet et al (2012) it was demonstrated that bromocriptine was well 
tolerated with no thrombotic complications (24). Moreover, although bromocriptine stopped 
lactation and breastfeeding in PPCM patients, the growth and survival of those infants were 
24 
 
normal. However, the study was very small and the findings were not definitive. On the other 
hand, these findings are encouraging and suggests that a larger study should be considered. 
A first larger prospective German PPCM cohort study looked at the aetiology, risk factors, 
underlying pathophysiology, co-morbidity, prognosis, biomarker profile and therapeutic 
concepts of PPCM in Western European societies. A high percentage of patients in this cohort 
study were treated with prolactin blocker, bromocriptine, in addition to standard treatment 
for heart failure.  This study suggested that patients obtaining the combination of the three 
(ACE inhibitors/ARB, beta blocker and bromocriptine) may have a higher chance for partial 
and full recovery (26). A larger, multicentre, randomised study evaluating bromocriptine on 
top of standard care, versus standard care alone, is currently underway (27).  
 
The EuroObservational Registry on PPCM (www.esc.org), which will have outcome on 1000 
patients with PPCM, many on bromocriptine, will provide additional information. As PPCM 
presents heterogeneously, has a spontaneous recovery rate even without therapy and the 
fact that therapy with bromocriptine cannot be blinded makes a well-powered multicentre 
study difficult (27).  
 
In a multicentre trial  conducted by Hilfiker- Kleiner et al (2017), 63 PPCM patients with LVEF) 
<35% were randomly assigned to short-term (1W: bromocriptine, 2.5mg, 7 days) or long-term 
bromocriptine treatment (8W, 5mg for 2 weeks followed 2.5mg for 6 weeks), in addition to 
SHFT (28).    
 
Bromocriptine treatment was associated with a high rate of full LV recovery and low morbidity 
and mortality in PPCM patients, compared with other PPCM cohorts not treated with 
bromocriptine. No significant differences were observed between 1W and 8W treatment, 
suggesting that 1 week addition of bromocriptine to SHFT  is already beneficial, with a trend 
for better full recovery in the 8W group (28).    
 
VGF SIGNALLING AND PRE ECLAMPSIA 
 
A study by Bello, Rendon et al (2013) showed that the prevalence of pre-eclampsia, 
hypertensive disorders and multiple gestations in women with PPCM is markedly higher than 
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in the general population. Their findings supported the concept of shared pathogenesis 
between pre-eclampsia and PPCM and highlighted the need for awareness of the overlap 
between these two diseases. Another antiangiogenic factor that is released in high quantities 
from the placenta during mid to late gestation is sFTL-1. A markedly elevated serum level of 
sFTL-1 has been associated with pre-eclampsia, a common maternal complication of mid- to 
late gestation that affects 3-5% of pregnancies worldwide (29). 
 
Another study by Rana, Powe et al (2012) showed that in women with suspected pre-
eclampsia presenting ≤34 weeks, circulating sFLT-1/PIGF ratio predicts adverse outcomes 
occurring within 2 weeks. Despite these finding the authors of the study concedes that 
additional studies are warranted to validate these findings (30). 
 
Some reports indicate that pre-eclampsia frequently occurs in patients who subsequently 
develop PPCM. A study by Patten, Rana et al (2012) showed a potential connection between 
the two diseases. In that study, a mice developed PPCM that is associated with an increased 
level of sFLT-1 and insufficient upregulation of cardiac expression of VEGF, a potent 
proangiogenic factor that is antagonised by sFLT-1. This model of PPCM also shows 
compromised protection from oxidative stress and enhanced cleavage of prolactin. PPCM was 
ameliorated by the addition of recombinant VEGF (rVEGF) or bromocriptine, but full rescue 
from PPCM was obtained only with combination of rVEGF and bromocriptine. These results 
suggest that PPCM might be a "two-hit" phenomenon. Firstly, systemic antiangiogenic signals 
occur during late pregnancy. Secondly, antiangiogenic factors are further upregulated during 
the peripartum phase, together with host susceptibility in the form of insufficient local 




MULTIPLE PREGNANCIES, PARITY AND MATERNAL AGE  
Earlier series of patients with PPCM suggested that the syndrome was more prevalent in older 
women. However, more recently, the clinical entity has been demonstrated to occur in 
women with a wide range of ages. In the original description by Demakis and Rahimtoola et 
al (1971), where he proposed clinical criteria for diagnosing the condition, he included 27 
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patients with the diagnosis of PPCM. Fourteen of these patients were older than 30 years, 
while 13 patients were younger than 30 years of age(31).  
 
A study by Gunderson, Croen et, al (2011) demonstrated in a large, multi-racial and ethnic 
pregnancy cohort in Northern California, that approximately one of every 2066 pregnant 
women who delivered a live born neonate developed confirmed PPCM. The strongest 
independent risk factor for PPCM was a maternal age of 40 years or older. The lowest risk of 
PPCM was associated with a maternal age younger than 24 years (32). In the United States of 
America, a National Hospital Discharge Survey was conducted of 3.6 million patient’s 
discharges from 1990 to 2002. There were an estimated 16296 cases of PPCM from 1990 to 
2002. Patients with PPCM were older, with ae mean age of 29.7 years (12). 
 
A South African single-centre study of 176 newly diagnosed patients with PPCM at 
Baragwanath Hospital looked at predictors of outcome in patients with PPCM. Clinical 
assessment, echocardiography and laboratory results were obtained at baseline and at 6 
months. Older age appears to be a novel predictor of LV recovery, while younger age, low 
BMI, increased left ventricular end diastolic diameter (LVEDD), increased left ventricular end 
systolic diameter(LVESD) and a higher  New York Heart Association (NYHA) functional class all 
seem to be predictors of mortality (33). 
 
Recently, Shani, Kuperstein et al (2014) conducted a retrospective cohort study of 36 women 
diagnosed with PPCM in a tertiary medical centre and compared the findings with 10370 
women who gave birth during a single calendar year at the same institution. Women 
diagnosed with PPCM were older (mean 33.5 years) than the controls. In most of these 
studies, the prevalence was highest in women in the higher and lower extremes of child-
bearing age. 
 
PPCM has been documented in primiparous and multiparous women. The researchers 
demonstrated that a significantly higher proportion of women with PPCM (63,9%) were 




A recent study by Hilfiker- Kleiner et al (2017) showed that age, gravida and twin pregnancies, 
hypertension in pregnancy, and/or smoking did not differ between patients with fully 
recovered cardiac function after SSP and those who remained in heart failure or died, 
suggesting that these factors do not have a substantial impact on SSP outcome (35).  
 
GENETIC PREDISPOSITION ESPECIALLY THOSE WITH AFRICAN DESCENT 
The PPCM high incidence areas of South Africa and Haiti reinforce the potentially strong 
genetic influence for those with African heritage. In one large study, Brar, Khan et al (2007) 
identified a significant difference in the incidence of PPCM in ethnic groups in the USA: 1 per 
1421 in African-American women and 1 per 2675 in Asian women, but that the greatest 
incidents of PPCM occurred in African-American women, which was 2.9-fold higher compared 
with Whites and 7-fold higher than in Hispanics in the USA (10). In another study Kao, Hsich 
et al (2013) identified clinical features associated with PPCM and possible racial differences. 
Hospital records from six USA states were screened for PPCM.  In total, 535 of 4003914 
records of delivering mothers specified a diagnosis of PPCM. The prevalence of PPCM was 
highest among African-Americans and similar in Caucasians and Hispanics. Established risk 
factors including maternal age above 30 years, African-American race, hypertension, 
preeclampsia/eclampsia and multi gestational status were associated with PPCM (36). 
 
In a more recent study Hilfiker-Kleiner, Haghikia et al (2017) found that the prevalence of 
patients entering SSPs with persistently reduced LVEF was higher among patients of African 
ethnicity. In addition, three out of four patients who died during or after SSP were African 
women, suggesting that they may indeed have a higher risk of a fatal outcome of SSP (28).  
 
PROLONGED TOCOLYSIS 
Prolonged tocolysis refers to the use of tocolytic agents for a period greater than four weeks 
(37). Pulmonary oedema occurring in the peripartum period has long been associated with 
the administration of tocolytic drugs, which include terbutaline, salbutamol, isoxsurprine and 
magnesium sulphate (38). Beta adrenergic agonists are commonly used as tocolytic agents, 
and act by increasing intracellular levels of cyclic adenosine monophosphate, which decreases 
the activity of myosin light chain kinase, the rate limiting enzyme in the signal pathway to 
uterine contraction. The physiological effects of these beta mimetic drugs, which include 
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tachycardia, hyperglycaemias, hypokalaemia, and water retention, are modulated by their 
interaction with beta1 and beta2 receptors (39). 
 
SELENIUM AND MALNUTRITION 
Nutritional disorders, such as deficiencies in selenium and other micro nutrients, were 
thought to play a role in the pathogenesis of PPCM. Deficiencies of selenium increase 
cardiovascular susceptibility to viral infections, hypertension and hypocalcaemia. However, 
Fett (2013) concluded that neither low serum levels of  selenium nor deficiencies of other 
micronutrients (vitamin A, B12, C, E and ß-carotene) played a significant role in the 
development of PPCM in Haitian women (40). In contrast, Cenac, Simonoff et al (1992) found 
that women from the Sahelian region of  Niger in Africa had low levels of selenium (41). A 
Nigerian case control study, conducted  in three hospitals in 2015,  aimed to determine if 
selenium deficiency, serum ceruloplasmin and traditional birth practices are risk factors for 
PPCM and PPCM patients were followed up for six months. A total of 39 PPCM patients and 
50 controls were consecutively recruited. This study showed that selenium deficiency is a risk 
factor for PPCM in Kano, Nigeria, and is related to rural residency. However, serum 
ceruloplasmin, customary birth practices and some other characteristics were not associated 
with PPCM in the study area (42). 
 
DIAGNOSIS AND CLINICAL MANIFESTATION OF PPCM 
 
PPCM is a diagnosis of exclusion - all patients should have a thorough investigation to identify 
any alternative aetiology of heart failure. Both cardiac and non-cardiac causes of symptoms 
should be considered. Fig 2 demonstrates an example of a diagnostic approach to  patients 
presenting in heart failure(43). 
 
The diagnosis of PPCM is based on symptoms and clinical findings in combination with 
appropriate investigations such as electrocardiogram (ECG), chest X-ray, biomarkers (e.g. 
BNP) and echocardiography (Fig 1). Recently, Blauwet, Libhaber et al. (2013) showed in a 
prospective cohort study of 176 African women, in a single tertiary institution, in a large series 
of patients from South Africa, that increased left-ventricular end systolic diameter (LVESD), 
lower body mass index (BMI) and lower serum cholesterol at baseline, possibly as a marker 
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of increased immune activation, may be independent predictors of poor outcome in patients 
with PPCM, while older age and smaller LVESD at baseline appear to be independently 
associated with a greater chance of LV recovery,(33). 
 
According to Sliwa, Tibazarwa et al (2008), clinical features of normal pregnancy include 
increased blood volume, increased metabolic demands, mild anaemia, changes in vascular 
resistance associated with mild ventricular dilatation and increased cardiac output. Thus, the 
onset of PPCM can easily be masked and missed because the manifestations can mimic those 
of mild heart failure. Women with PPCM most commonly have dyspnoea, dizziness, chest 
pain, cough, neck veins distention, fatigue and peripheral oedema (44). A study by Pearson 
Veille (2000) illustrates that women with PPCM can also have arrhythmias, embolic events 
due to the dilated, dysfunctional left ventricle, and acute myocardial infarction due to 
decreased perfusion to the coronary arteries (6). They can also have other indications typical 
of heart failure: hypoxia, jugular venous distention, S3 and S4 gallop rhythm, rales and 
hepatomegaly. Blood pressure is often normal or decreased, and tachycardia is common (5). 
The definitive diagnosis of PPCM depends on echocardiographic identification of new- onset 
heart failure during a limited period around parturition. A diagnosis of PPCM requires the 
exclusion of other causes of heart failure such as myocardial infarction, sepsis, severe 
eclampsia, pulmonary embolism, valvular disease and other forms of cardiomyopathy (45). 
 
Chest radiographs should be obtained in suspected cases of PPCM. These radiographs may be 
helpful in acute pulmonary oedema, but much less so if no clinical evidence of pulmonary 
congestion and pleural effusions are evident (46). However, diagnosing cardiomegaly on the 
basis of a chest radiography in a pregnant patient is difficult because the heart is pushed 
upwards and laterally, giving the false impression of cardiomegaly. Electrocardiograms should 
also be obtained. In PPCM, the tracings may be normal or may show left ventricular 
hypertrophy, ST-T wave abnormalities, dysrhythmia, Q-waves in the anteroseptal precordial 
leads and prolonged PR and QRS intervals (5). Several laboratory tests should be performed: 
complete blood counts and serum levels of troponin, urea, creatinine, and electrolytes (44). 
Liver function tests should be done and levels of thyroid stimulating hormone should be 
measured. In the initial evaluation, the serum level of troponin may be helpful in ruling out 
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myocardial infarction. However, an increase in troponin in the acute phase of PPCM, without 
myocardial infarction can occur (46). 
 
According to Ntusi and Mayosi (2009) measuring levels of B-type natriuretic peptide and N 
terminal pro B-type natriuretic peptide can help in confirming the diagnosis (13). 
 
Echocardiography is a non-invasive investigation and allows serial evaluations in pregnant 
women (47). In a study by Sliwa, Tibazarwa et al (2008), they demonstrated that serial 
echocardiography with Doppler imaging is used to evaluate and monitor regional and global 
left and right ventricular function, valvular structure and function, possible pericardial 
pathological changes, and mechanical complications. Findings in women with PPCM are 
consistent with that of those in heart failure: decreased EF, global dilatation, and thinned out 
cardiac walls (44). 
 
STANDARD TREATMENT STRATEGY 
 
The management of heart failure around pregnancy is challenging and according to ESC 
guidelines there is significant peculiarities and challenges (Box1) (48). In the absence of 
evidence–based data, the initial management of patients with PPCM is similar to 
management of AHF of other aetiologies. Interdisciplinary approaches of cardiologists, 
intensivists, obstetricians, neonatologists, anaesthetists and cardiac surgeons are necessary 
in cases of severe AHF. Fig 3 demonstrates an example of interdisciplinary work-up of a 
patient with heart failure in pregnancy (48). The initial treatment of patients with confirmed 
PPCM without cardiopulmonary distress depends on the time-point of onset. Patients who 
present after delivery should be treated according to the ESC guidelines for heart failure (48). 
For patients presenting during pregnancy, joint cardiac and obstetric care in observance of 
the ESC guidelines for management of cardiovascular disease in pregnancy is recommended 




Patients with signs of cardiopulmonary distress and /or circulatory shock need rapid and more 
aggressive therapy and should be admitted to the intensive care unit. Initial therapy includes 
five main elements: optimization of the preload , optimization of oxygenation, restoration of 
haemodynamics with inotropes and/or vasopressors; urgent delivery if heart failure occurs 
during pre-partum; and consideration of adjunctive therapies with bromocriptine (2.5mg 
twice daily for 2 weeks, followed by 2.5mg per day for 6weeks) (48). Patients with 
haemodynamic instability despite treatment should undergo urgent delivery irrespective of 
gestation duration. Caesarean section with combined spinal and epidural analgesia and 
involvement of an experienced interdisciplinary team are recommended (49). 
 
Management of patients with acute peripartum cardiomyopathy without cardiopulmonary 
distress depends on the time point of onset. Patients who presents after delivery should be 
treated according to the ESC guidelines for heart failure (49). For patients presenting during 
pregnancy, joint cardiac and obstetric care in observance of cardiovascular diseases in 
pregnancy is recommended. During pregnancy, ACE inhibitors, ARBs and renin inhibitors are 
contraindicated because of foetal toxicity. Hydralazine and nitrates can be used instead. After 
delivery ACE inhibitors can be started, but during breastfeeding captopril or enalapril should 
be preferred. Despite an increased risk of foetal growth restriction, beta blockers are 
indicated in all patients in a stable condition. Mineralocorticoid receptor antagonists (MRA) 
should be avoided during pregnancy and lactation, but should be started afterwards in stable 
patients. Diuretics should be administered with caution during pregnancy as they may impair 
perfusion of the placenta (48). Bromocriptine, in addition to the heart failure therapy, should 
be considered because it has shown promising results, with improved LV systolic function and 
clinical outcomes in several case studies (24). In the multicentre randomised study by Hilfiker- 
Kleiner et al (2017) on the benefit of bromocriptine for the treatment of PPCM it was 
demonstrated that bromocriptine treatment was associated with a high rate of full LV 
recovery and low morbidity and mortality in PPCM patients, compared with other PPCM 
cohorts not treated with bromocriptine. In this multicentre trial, 63 PPCM patients with LVEF 
<35% were randomly assigned to short-term (1W: bromocriptine 2.5mg, 7 days) or long-term 
bromocriptine treatment (8W: 5mg for 2 weeks, followed by 2.5mg for 6 weeks), in addition 
to SHFT. No significant differences were observed between 1W and 8W treatment, suggesting 
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that 1 week addition of bromocriptine to SHFT is already beneficial with a trend for better full 
recovery in the 8W group (28). 
 
While diuretics should be tapered when possible after stabilization and when LVEF improves, 
ACE inhibitors, beta blockers, and MRAs should probably be given in guideline- based dosages 
and not discontinued during the first 12 months after complete recovery of LV dimensions 
and systolic functions. Earlier, stepwise discontinuation of heart failure therapy might be 
considered if both complete recovery of ventricular function and normal exercise response 
are achieved. Ivabradine should be given according to established indications. Furthermore, 
early treatment with Ivabradine even before or parallel with beta blockers may be considered, 
as it appears to be safe and effectivei(50). 
 
Prevention of sudden cardiac death 
Severely impaired ventricular function is associated with increased risk of life-threatening 
arrhythmias.  Current ESC guidelines for treatment of heart failure recommend implantation 
of ICD (implantable cardioverter defibrillator) for primary prevention in patients with 
symptomatic heart failure and LVEF ≤ 35%,  despite optimal pharmacological treatment  or 
for secondary prevention in patients with documented ventricular arrhythmia causing 
haemodynamic instability (51). In the context of PPCM, where a young women with the 
potential for complete recovery of ventricular function are involved, decision about 
implantation of ICD should be taken with caution. After diagnosis of PPCM, clinicians are faced 
with the uncertainty about the subsequent evolution of ventricular function. Therefore, the 
related decision of whether to implant an ICD or not may be very challenging (48). 
 
Several publications reported recovery of LV function in at least 50% of patients within 6 
months after diagnosis (52). However, a Turkish study reported a delayed recovery (after 6 
months) in a significant proportion of patients (53). In the year 2014 in United States of 
America,  a retrospective study showed a complete recovery of LV function in 23% of patients 
and partial recovery in another 19%, over a mean duration of 33±21 months, confirming 
frequent delayed recovery over 6 months (83%) In that study, Afro-Americans women 
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showed a lower rate of recovery compared to Caucasians and post-partum diagnosis  was a 
predictor of good recovery (54). In a South African study, age and low end diastolic diameter 
were predictors of recovery, whereas LVEF was not (33). In light of these findings, early 
implantation of an ICD in patients with newly diagnosed PPCM is not appropriate. However, 
postponement of ICD implantation beyond the time point when further recovery of 
ventricular function is unlikely (6 – 12 months) exposes young mothers to an unacceptable 
risk of sudden death. Novel therapies such as a wearable cardioverter-defibrillator (WCD) are 
an interesting alternative for the prevention of sudden cardiac death in the first months after 
diagnosis, until a definitive decision about ICD implantation can be made (35). 
 
In patients without recovery despite 3-6 months on optimised heart therapy, a conventional 
recommendation for the primary prophylactic implantation of an ICD applies (51). In patients 
without Left bundle branch block (LBBB) or symptomatic sick sinus syndrome, single chamber 
ICDs are recommended. Subcutaneous ICDs (S-ICD) represent an alternative to Trans-venous 
systems in these young patients. Subcutaneous systems avoid intravascular leads and, thus, 
the potential complication of infections leading to endocarditis and lead extractions. On the 
other hand, subcutaneous systems can provide neither anti-tachycardia pacing (ATP) nor 
post-shock pacing and, therefore, might not be an optimal choice for patients with recurrent 
ventricular tachycardia successfully terminated by ATP (43). In patients with heart failure, 
LVEF ≤ 35% despite optimal medical therapy for at least 3-6 months and LBBB, cardiac 
resynchronization therapy (CRT) is indicated, although no large studies have assessed the 
value of CRT in patients with PPCM. Significant improvement of LV function in two PPCM 
patients undergoing CRT device implantation for persistent symptomatic LV dysfunction was 
reported (55). According to the current ESC guidelines on CRT, in patients with symptomatic 
heart failure, persistent LVEF ≤35% and complete LBBB (QRS duration >130ms), CRT should 
be offered. In patients with wide QRS complex with non-LBBB morphology (QRS duration 
>150ms) CRT may be considered (51). Although no data on device therapy in patients with 






LITERATURE REVIEW  
 
REVIEW ON MATERNAL OUTCOME ON SUBSEQUENT PREGNANCY IN PATIENTS WITH PPCM 
In a study by Elkayam, Tummala et al (2001) an early survey was conducted that relied solely 
on a questionnaire filled out by physicians. They obtained information about SSPs s in women 
who had PPCM by sending out a questionnaire, in 1997 and 1998, to all members of the 
American College of Cardiology in the United States (approximately 15,000 persons) and to 
two members of one cardiology group in South Africa, seeking information about women with 
PPCM who had SSPs. Of the approximately 15,000 physicians contacted, 409 returned the 
questionnaire. On the basis of responses, they identified 92 women with a history of PPCM 
who had a SSP. The survey was aimed at assessing the maternal and foetal outcomes of SSPs 
in women with PPCM (56).  
 
Maternal outcome during the first SSP indicated that 6 of the 28 women in group 1 (21%) and 
7 of the 16 women in group 2 (44%) had symptoms of heart failure. Twenty one of the women 
in group 1 and 25% of those in group 2 had a decrease of more than 20% in the left ventricular 
EF during the first SSP, and 14% of the women in group 1 and 31% of those in group 2 had a 
decreased ejection fraction at the last follow-up. None of the women in group 1 died during 
or after the first SSP. Two of the women died suddenly (one died two months following SSP, 
and the other two years after the SSP). One woman died of progressive heart failure two 
months after the SSP. This study demonstrated that in women who had PPCM, SSPs may be 
associated with deleterious foetal and maternal outcomes such as premature delivery and 
maternal cardiac dysfunction, including symptomatic heart failure and even death (56). 
 
Another study by Avila, de Carvalo et al (2002) reported no maternal complications in 6 
patients with SSPs with normal LV function and the development of heart failure in 30% of 11 
patients, with LV dysfunction that was associated with pulmonary embolism in 1 patient and 




A South African study by Sliwa, Forster et al (2004) reported on 6 indigenous black South 
African women known to have PPCM (ages 26 to 39) who had a SSP. This was the first 
prospective study of left ventricular function and cytokine measurement in women with 
documented PPCM with SSP.  Four patients were Para 2 and gravida 2 and two were Para 3 
and gravida 3. The SSP occurred 1 to 2 years after the initial pregnancy in all patients. None 
were twin or multiple pregnancies and none of the patients had pregnancy related 
hypertension or eclampsia. All had normal vaginal delivery at term. All 6 patients were in 
NYHA class I at the onset of SSP and remained asymptomatic until delivery. All patients 
developed heart failure in the postpartum period and were placed on optimal anti failure 
treatment.  Unfortunately, two patients died within 8 weeks after delivery from severe 
refractory heart failure despite admission to intensive care unit and optimal medical 
treatment. The remaining 4 patients continued to remain asymptomatic. Deterioration of left 
ventricular function occurred uniformly postpartum. Both deaths occurred in patients who 
had persistent cardiomegaly and impaired EF at onset of SSP (58). 
 
A Chart review study by Chapa, Heiberger et al (2005) of patients with PPCM between 1988 
and 2001. Data from echocardiography, including fractional shortening and left ventricular 
end diastolic dimension, were recorded both at the time of diagnosis and at follow-up. Left 
ventricular dysfunction was defined by echocardiography as a fractional shortening less than 
30 degrees and left ventricular end diastolic dimension of 4.8 cm or more. The results of the 
study showed 13 (41%) patients had recovery of ventricular function, while 19 (59%) 
continued to have persistent left ventricular dysfunction. Those who did not recover cardiac 
function had a higher left ventricular end diastolic dimension and a lower fractional 
shortening at diagnosis than those who recovered. A fractional shortening of less than 20% 
and a left ventricular end diastolic dimension 6 cm or greater at the time of diagnosis was 
associated with a more than 3-fold higher risk for persistent left ventricular dysfunction (59). 
 
A Haitian observational study by Fett, Christie et al. (2006) focused on Haitian women with 
SSPs among 99 prospectively identified patients with PPCM who were enrolled in the Hospital 
Albert Schweitzer Peripartum Cardiomyopathy Registry from 1 February 2000 to 31 January 
2005. Patients had a clinical and echocardiographic examination at least every 6 months and 
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were counselled to avoid pregnancy until ventricular function returned to normal. They 
identified 16 SSPs in 15 patients with PPCM who had an index pregnancy with a diagnosis of 
PPCM. Mean interval between the index pregnancy and delivery of SSP was 26 months (range, 
16 to 37 months). All but 1 patient with SSP became pregnant before full recovery of left 
ventricular function and against medical advice. Eight of 15 patients (53%) had worsening 
heart failure during SSP, and only one of these patients regained normal left ventricular 
systolic function after the SSP. One patient died of severe heart failure 10 months after SSP. 
Seven patients (47%) showed no worsening heart failure with SSP and they recovered normal 
left ventricular systolic function during or after the SSP. One patient had 2 SSPs  after the 
index pregnancy, with worsening heart failure occurring after the second SSP, but not after 
the first SSP (60). 
 
A study in United States of America by Habli, O Brien et al (2008) assessed the prognostic 
value of EF at index and SSP on long-term outcome in patients with PPCM. It was a 
retrospective analysis of data on patients with a diagnosis of PPCM, from January 2000 to 
January 2006, at the University of Cincinnati in Cincinnati, Ohio. The overall follow-up period 
from index pregnancy to last available follow-up was 3.4 ± 1.9 years (range, 1 - 6 years). The 
mean interval between a pregnancy complicated with PPCM and a first SSP in those who had 
early termination or successful SSPs was 2.19± 0.7 and 2.7 ± 0.5 years, respectively. There 
were no statistical significant differences among the groups with regard to LVEF at the index 
pregnancy, at interval follow-up or at the first SSP, and at the last follow-up available. 
Persistent left ventricular dysfunction was noted in women with PPCM and no SSPs and in 
those who had early termination during the follow-up period, as compared with those with 
successful SSPs. Among the 70 patients with PPCM, 28 (40%) had an EF of 25% or less and 42 
(60%) had an EF greater than 25%. Among those with EF of 25% or less, 57% (n=16) had an 
end-stage cardiac disease requiring cardiac transplant, as compared with none who had end-
stage cardiac disease if EF was greater than 25%. Their findings revealed that women with 
PPCM with a baseline LVEF 25% or less at the time of diagnosis is associated with a poor long-
term outcome and a higher rate of subsequent need for cardiac transplant. They also revealed 
that SSPs in women with PPCM have a deleterious maternal effect on maternal cardiac 
37 
 
function, as manifested by either worsening cardiac symptoms or persistent cardiac left 
ventricular dysfunction(61). 
 
In a study by Williams, Mozurkewich et al (2008) it was suggested that dividing women into 2 
categories (recovered vs non-recovered left ventricular function) is most appropriate for 
counselling on future pregnancies. Even though the cardiac function has normalised in the 
group of women with recovered cardiac function, the left ventricular contractile reserve may 
remain impaired and recurrence of PPCM is still possible (46). 
 
A study in United States of America by Modi, Illum et al (2009), conducted  in the United 
Stated, looked at the clinical and echocardiographic  data of 44 (39 African-American women) 
patients with PPCM over an 11 year period (1992-2003). During a mean follow-up of 24 
months, 7 (15.9) patients died and LV function returned to normal in 14 (35%). The study 
concluded that LV function recovery and survival rates of PPCM patients observed in this 
study are similar to those reported from Haiti and South Africa and different to what is 
generally accepted in the United States (62). 
 
In 2010 Fett, Fristoe et al (2010) conducted a study to assess the risk of heart failure relapse 
in SSPs in PPCM women. Prospectively identified PPCM patients, volunteering between 2003 
and 2009, were identified from the PPCM Registry of Hospital Albert Schweitzer, in Haiti. Of 
the 61 post PPCM pregnancies identified, there were 18 relapses (29.5%) of heart failure. Of 
the 26 pregnancies with a LVEF of less than 55% prior to the pregnancy, relapse occurred in 
12 (46.2%) pregnancies. Of the 35 pregnant women with an LVEF of 55% or greater prior to 
the pregnancy, relapse occurred in 6 (17, 1%)  (P<0.01). No relapses occurred in 9 women 
who also demonstrated adequate contractile reserve (63).  
Mandal, Mandal et al (2011) conducted a study in India to analyse the pregnancy outcomes 
of pregnant women with PPCM, as well as its effect on SSPs. All patients hospitalised with 
PPCM between July 2006 and June 2009 in the Departments of Cardiology and Obstetrics and 
Gynaecology at the Institute of Post Graduate Medical Education were included in the study. 
A total of 36 women aged between 15 and 45 years, with 42 pregnancies (36 first pregnancies 
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and 6 second pregnancies) were analysed. Patients were evaluated by physical examination, 
investigations (routine blood examinations, electrocardiography [CXR, posterior-anterior 
views] and echocardiography). Maternal outcome was assessed by documenting associated 
complications and maternal death. Primiparus constituted 39% (14/36) of the total study 
population. Twenty six women (72%) were clinically improved and in 17 (48%) the left 
ventricular functional status returned to normal. Five cases (14%) developed persistent 
cardiomyopathy (persistent left ventricular dysfunction beyond six months of presentation), 
and 5 women (14%) presented with thromboembolic events and anticoagulation was used as 
secondary prophylaxis. Maternal mortality was 14% (5/36). Of the 6 women with SSPs, one 
patient with persistent cardiomyopathy died after delivering a stillborn baby. The remaining 
5 cases with normal left ventricular functional status had favourable foetal outcomes; 
however, the mothers experienced morbidities such as symptoms of heart failure (two cases) 
and one of them progressed to persistent cardiomyopathy (64). 
 
A recent study by Hilfiker- Kleiner et al (2017) on the outcome of  subsequent pregnancies in 
patients with a history of peripartum cardiomyopathy. Subsequent pregnancies (SSP) in 34 
patients  with clearly diagnosed index PPCM were treated and /or managed either at 
university hospitals, in tertiary  hospitals, or by cardiologists in private practice in South Africa, 
Scotland and Germany.  12% of the pregnancies ended prematurely and the rest were full 
term. Overall relapse rate (LVEF≤ 50% or death after at least 6 months) was 56%, with 12% 
mortality. Persistently reduced LVEF (≤ 50%) before entering SSP was present in 47% of 
patients, while full recovery (LVEF ≥ 50%) was present in 53%. The majority of patients 
entering SSP with persistently reduced LVEF were of African ethnicity (75%).  Persistently 
reduced LVEF before SSP was associated with a higher mortality (25% vs 0%) and a lower rate 
of full recovery at follow-up (35). 
 
FETAL OUTCOME ON SUBSEQUENT PREGNANCY IN PATIENTS WITH PPCM 
There is limited information available on the foetal outcome in SSPs of patients with PPCM. A 
survey by Elkayam, Tummala et al (2001) of members of the American College of Cardiology 
identified 44 women who had PPCM and had a total of 60 subsequent pregnancies (SSP). They 
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reviewed the medical records of these women and interviewed their physicians. Among the 
35 women who had a SSPs and did not have an abortion, 21 had a normal vaginal delivery and 
14 delivered by Caesarean section. Premature delivery (defined as delivery at less than 37 
weeks gestation) occurred in 3 women (13% of the subgroup - women with normal LV 
function before SSP) in group 1, and in 6 women (50% of the subgroup - women with 
persistent LV dysfunction before SSP) in group 2. There was no perinatal mortality. Of the 9 
abortions, 5 were therapeutic (56). 
 
An Indian observational study by Mandal, Mandal et al (2011) assessed both maternal and 
foetal outcome in patients with PPCM.  All 36 mothers had given birth to neonates. The birth 
weight of the babies ranged from 800 to 900 grams. Two premature babies with Apgar scores 
of <8 suffered from asphyxia and subsequently died in the neonatal period. Another 2 had 





Our local ethics committees approved this study. SSPs in 18 patients with clearly diagnosed 
index PPCM were managed or treated at university hospitals, tertiary hospitals, or by 
cardiologists in private practice in South Africa. All 18 PPCM patients with SSPs matched the 
diagnostic criteria for PPCM at their index PPCM (LVEF ≤45%) and had absence of previously 
known cardiomyopathy. All patients provided written informed consent. Minimal 
requirement for enrolment was fulfilling the criteria for the diagnosis of PPCM, including 
availability of baseline LVEF at the index pregnancy and LVEF after SSP. Clinical and laboratory 
assessments were performed in all 18 patients with confirmed index PPCM at the time of 






ANALYSIS OF OUTCOME 
 
 Patients were classified with regard to recovery according to the 2016 ESC guidelines defining 
preserved LV function as LVEF ≥49%. Accordingly, patients were defined as entering SSP with 
fully recovered function if LVEF was ≥50% and persistently reduced LV function if LVEF was 





Table 1: Clinical presentation and outcome of subsequent pregnancies (SSPs) in patients 
entering SSP with persistently reduced (LVEF≤50%) or fully recovered left ventricular 
function (LVEF≥50%) 
 
 LVEF ≤50%(n=11) LVEF ≥50%(n=7) 
LVEF(%)at diagnosis of index PPCM(mean) 34% 30.4% 
LVEF(%)before SSP(mean) 44% 56% 
LVEF(%)after delivery of SSP(mean) 38% 54% 
LVEF(%)SSP follow-up(mean) 30% 43% 
Full recovery from PPCM after SSP 18%(2/11) 85%(6/7) 
Death 27%(3/11) 0%(0/7) 







Table 2: Comparison of cardiac and clinical parameters in patients receiving standard 
therapy for heart failure alone or with addition of bromocriptine 
 
 SHFT + BR (N=10) SHFT(N=8) 
LVEF % At index PPCM(mean) 34% 32% 
LVE F% before SSP(mean) 47% 48% 
LVEF ≥50% prior SSP(mean) 57% 56% 
LVEF % after SSP(mean) 51% 35% 
LVEF % at follow-up SSP(mean) 49% 30% 
Full recovery from PPCM after SSP 60%(6/10) 12.5%(1/6) 
 
Note: SHFT= standard heart failure treatment; LVEF= left ventricular ejection fraction; PPCM 
= peripartum cardiomyopathy; SSP= subsequent pregnancy; BR=bromocriptine. Early after 
delivery of SSP was measured in the first few days after delivery before discharged, when 
medical treatment had already started. Follow-up LVEF after SSP was analysed at least 6 










Patients in Table 1 were divided into a group entering SSP with persistently reduced LVEF 
(≤50%) and a group with fully recovered LVEF (≥50%). 
  
Gravity, cardiac function at index peripartum cardiomyopathy and at delivery of 
subsequent pregnancy 
The 18 PPCM patients presented with a mean LVEF of 33% at the index pregnancy and a mean 
of 48% before SSP. The median gravity at SSP in all 18 patients was 2. The follow-up data, 6 
months post SSP, 3 patients had died and mean LVEF 42%. Recovered PPCM (LVEF ≥ 50%) at 
follow-up was observed in 40% (6/15). Persistent reduced LVEF (≤ 50%) was present in 60% 
(9/15). The overall mortality rate in this collective of PPCM patients with SSP was 16% (3/18). 
 
Clinical presentation and outcome of subsequent pregnancies in patients who entered 
subsequent pregnancies with recovered versus not recovered left ventricular function 
To analyse the effect of LV function before SSP in our group, we divided patients into those 
who displayed full recovery (LVEF≥50%) and those who had reduced LVEF (≤50%) when 
entering SSP. Full recovery from PPCM before SSP was observed in 7/18 patients, while 
persistent reduced LV function was present in 11/18patients. Among the 11 patients entering 
SSP with unrecovered LV function, 3 patients had died at 6 months follow-up. Their mean 
LVEF early after delivery was significantly lower compared with the 7 patients entering SSP 
with fully recovered LV function. At follow-up (6months after delivery), the proportion of 
patients with stable full recovery(LVEF≥50%) tended to be higher in patients entering SSP with 







Outcome of patients receiving standard therapy for heart failure alone or with addition of 
bromocriptine immediately after delivery of subsequent pregnancy 
All 18 patients received beta-blocker therapy and ACE inhibitors, defined as SHFT. Of these, 
10 patients received SHFT and bromocriptine (which was started immediately after delivery) 
and 8 received SHFT alone. No significant differences were observed between the two groups 
with regards to LVEF at the index PPCM, or LVEF before SSP (Table3).  A comparable 
proportion of patients in both groups entered SSP with recovered cardiac function (LVEF≥50) 
and received beta-blockers and ACE inhibitors. The SHFT + bromocriptine group displayed a 
trend to better LVEF in the first week after delivery, with significantly better LVEF at follow- 
up of SSP, compared with the group treated with SHFT alone (Table 2). More patients in the 
SHFT + bromocriptine group displayed full recovery from PPCM with LVEF ≥50% at follow-up, 
compared with patients in the SHFT group (Table 3). In addition, no patient in the SHFT + 
bromocriptine group died during follow-up of SSP, while 3 patients died in the SHFT group.  
 
DISCUSSION 
Previous studies suggest that some degree of cardiac dysfunction recurs in most PPCM 
patients in the postpartum phase of an SSP, with a higher risk for adverse outcome when LV 
structure and functions had not completely recovered before SSP(58). In this study we report 
data from two university hospitals in South Africa (Baragwanath and Groote Schuur Hospital). 
In our observation there was a significantly high risk of relapse of heart failure - more than 
half of our patients presenting with SSP in this study entered with LV function not fully 
recovered. These patients with persistently unrecovered LV function had a significantly high 
risk of fatal outcome of SSPs, as supported by all 3 patients who died after SSP had entered 
the SSP with LVEF ≤ 50%. Moreover, persistently reduced LV function before entering SSP was 
associated with lower cardiac function in the early phase after SSP delivery and had a lower 
chance for full recovery during the follow-up. Interestingly, in patients entering SSP with fully 
recovered cardiac function (LVEF≥ 50%), stable full recovery at follow-up of SSP was observed 
in 85%, showing that PPCM patients with fully recovered LV function have a reduced risk of 
relapse in SSP.  However, the number of patients in this study was too small to draw any major 
conclusions. The majority of the patients were treated with standard heart failure treatment 
(SHFT), as suggested by ESC guidelines. Only 10 patients received bromocriptine in addition 
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to SHFT, with 8 patients not receiving bromocriptine. The 3 patients who died were from the 
group that was treated with SHFT without bromocriptine. Whether addition of bromocriptine 
in addition to SHFT in this study was beneficial or not could not be evaluated as the number 
of patients was too small to draw conclusion. In a study by Hilfiker-Kleiner et al (2017) of 34 
patients with clearly diagnosed index PPCM from tertiary hospitals , cardiologists in private 
practice in South Africa, Germany  or Scotland between 2005 and 2015. They looked at the 
risk of relapse during or after a SSP. They observed that despite high risk of a relapse of heart 
failure, half of the patients presenting with an SSP in the study were entering it with LV 
function not fully recovered. These patients had a substantially higher risk of fatal outcome 
of SSP as all patients who died during or after SSP in the present study had entered the SSP 
with a LVEF that was not fully recovered. Moreover, persistently reduced LV function before 
entering SSP was associated with lower cardiac function in the early phase after SSP delivery 
and lower chance for full recovery during follow up. However, even in patients entering SSP 
with fully recovered cardiac function, stable full recovered at follow up of SSP was only 
observed in 56%, showing that PPCM patients with fully recovered LV function also have 







Counselling of all PPCM patients regarding the risk of worsening heart failure, and even death 
in SSP is of paramount importance as the risk is substantial, even in patients with recovered 
LV function before SSP. There is significant high risk of fatal outcome of SSP, particularly with 
persisting heart failure or death and is particularly high if patients enter SSP with a LVEF that 
is not fully recovered. In SSP in a PPCM patients, management by an interdisciplinary team of 
cardiologists, obstetricians, anaesthetists and neonatologists is recommended. All patients 
need to be monitored carefully for at least 6 months postpartum and, perhaps, lifelong. 
Despite major limitations such as small cohort size and non-randomised design, our data 
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suggest that progression of heart failure and fatal outcome of SSP may be prevented if a SHFT 
+BR therapy is initiated immediately after delivery in SSPs. However, larger and long-term 
outcome data are urgently needed. Unfortunately there was not enough data to comment on 
the foetal outcome of SSPs in our study. We recommend a large randomised controlled study 
to focus on both foetal and maternal outcome in SSPs in patients with documented PPCM. 
 
  Adapted from:(13) 








Fig 2: Diagnostic algorithm for a diagnosis of heart failure on non- acute onset : BNP= B type 
natriuretic peptide; CAD= coronary artery disease; MI= myocardial infarction; NT pro BNP= N 
terminal pro-B type natriuretic peptide(43) 
 
 







Box 1: Peculiarities in the management of acute heart failure caused by peripartum 
cardiomyopathy 
 Multidisciplinary approach with focus on health of mother and foetus. 
 Avoidance of heart failure (HF) drugs with foetal toxicity during pregnancy (i.e. ACE 
inhibitors/ARBs, mineralocorticoid receptor antagonists) and breastfeeding; thereafter 
 standard HF therapy 
 Consideration of bromocriptine (2.5 mg twice daily for 2 weeks, followed by 2.5 mg per day 
for 6 weeks) in addition to standard HF therapy. 
 Anticoagulation with heparin to avoid cardio-embolic complications in patients with LVEF 
≤35% or treated with Bromocriptine (if no contraindication exists). 
 In the case of cardiogenic shock, consideration of levosimendan (0.1 μg/kg/min for 24 h) 
instead of catecholamines as first-line inotropic drug. Early transfer to experienced centre. 
Early evaluation of mechanical circulatory support according to the centre’s experience. 
 Prevention of sudden cardiac death, early consideration of wearable cardioverter-




Fig 3: Example of interdisciplinary work-up for acute heart failure (AHF) during pregnancy 










Fig 4: Algorithm for initial management of PPCM: BB=beta blocker, HF=heart failure, 
RR=respiratory rate, SBP=systolic blood pressure, SpO2 peripheral oxygen saturation 










Fig 5: Time course of left ventricular ejection fraction at diagnosis index PPCM, 6 months 
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